Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.54 |
| ▸ | CNR1 | P21554 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.44 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13392769 | 0.86 | CNR2 (0.55) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL9958104 | 0.86 | CNR2 (0.58) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL9891815 | 0.85 | CNR2 (0.54) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL9891520 | 0.85 | CNR2 (0.60) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL5031598 | 0.84 | ALDH1A1 (0.69) | CNR2CNR1ALDH1A1MAPK14 | |
| SCHEMBL9892942 | 0.84 | CNR2 (0.53) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL12566298 | 0.84 | CNR2 (0.59) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL2185599 | 0.81 | CNR2 (0.51) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL13001505 | 0.81 | CNR2 (0.60) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL30311273 | 0.81 | ALDH1A1 (0.44) | CNR2CNR1ALDH1A1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | CNR2 4544/4885CNR1 4436/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.